# Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

> **NCT05245474** · PHASE2 · RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 186 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **COMBINATION_PRODUCT:** Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)

## Key facts

- **NCT ID:** NCT05245474
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2024-01-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245474, "Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05245474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*